- Report
- October 2024
- 217 Pages
China
From €3803EUR$4,000USD£3,195GBP
- Report
- October 2024
- 93 Pages
China
From €1711EUR$1,800USD£1,438GBP
- Report
- September 2024
- 239 Pages
China
From €3803EUR$4,000USD£3,195GBP
- Report
- February 2024
- 106 Pages
China
From €1711EUR$1,800USD£1,438GBP
- Report
- January 2024
- 278 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- November 2023
- 107 Pages
China
From €1711EUR$1,800USD£1,438GBP
- Database
- July 2023
Global
From €342EUR$360USD£288GBP
- Report
- March 2018
- 102 Pages
Global
From €2614EUR$2,750USD£2,196GBP
- Report
- October 2021
- 110 Pages
Global
From €6512EUR$6,850USD£5,471GBP
- Report
- March 2025
- 115 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- November 2024
- 100 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2024
- 138 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2023
- 119 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2023
- 104 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2023
- 91 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Book
- September 2019
- 302 Pages
The Anticancer Agent market is a segment of the Healthcare Services industry that focuses on the development and distribution of drugs and treatments for cancer. These agents are designed to target and destroy cancer cells while minimizing the damage to healthy cells. They can be administered orally, intravenously, or topically, depending on the type of cancer and the patient's individual needs. Anticancer agents are used in combination with other treatments such as radiation and chemotherapy to provide the best possible outcome for the patient.
The Anticancer Agent market is highly competitive, with many companies vying for market share. Companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
